Partnering Agreements with Bristol-Myers Squibb

Date: January 1, 2010
Pages: 60
Price:
US$ 450.00
Publisher: CurrentPartnering
Report type: Reference Manual, Business Directory, Strategic Report, Company Report
Delivery: E-mail Delivery (PDF), CD-ROM Mail Delivery, E-mail Delivery (Word)
ID: P9A75D26AC2EN
Leaflet:

Download PDF Leaflet

Partnering Agreements with Bristol-Myers Squibb
Summary

The Partnering Agreements with Bristol-Myers Squibb 2010 provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.

This report provides all the information you require to better understand Bristol-Myers Squibb Labs and its partnering interests and activities over the past five years.

Description

Using this report, dealmakers will effectively and efficiently determine the suitablility of Bristol-Myers Squibb as a prospective partner, their business development objectives, interests and recent partnering activity, key partnering contacts, and partnering contract documents signed with their recent partners.

The report provides a firm basis for initial due diligence into Bristol-Myers Squibb as a prospective partner company.

The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2008 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers between 2005 and 2009 in M&A and partnering deals announced, whilst chapter 4 identifies the top deals of 2005 to 2009 according to reported deal size.

Chapter 5 provides details on how to approach bigpharma companies with partnering opportunities whilst chapter 6 lists forthcoming partnering events and conferences where bigpharma companies will be present to discuss opportunities face to face.

Chapter 7 provides a series of matrices that summarize the company’s activity in terms of marketed and pipeline products, partnering interests and partnering activity by therapeutic area.

The main body of the report is provided in chapter 8. An in-depth profile of the company provides everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company’s marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. The profile also includes in-depth contact information for individuals within the business development function.

The company profile is also provided with a comprehensive listing of contract documents available in the public domain. The listing is sorted by deal type – therefore co-promotion deals are listed separately to licensing, M&A and supply deals, and so on.

Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

In summary, the report provides the user with the tools to make successful contact with the right bigpharma partners effectively and efficiently.

Key benefits

Partnering Agreements with Bristol-Myers Squibb 2010 report provides the user with the following key benefits:

- Detailed company profile of the company
- In-depth marketed and pipeline product activity for the company
- Partnering interests and therapy focus revealed
- Partnering activity since 2000 – number of deals per year
- Partnering activity for 2005-2009
- Activity by deal type
- Activity by phase of development
- Activity by therapeutic area
- List of recent partner companies
- Comprehensive access to actual contracts entered into by the company and its partners
- Insight into the terms included in a partnering agreement
- Understand the key deal terms the company has agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Partnering Agreements with Bristol-Myers Squibb 2010 is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the company, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s approach to partnering.

Partnering Agreements with Bristol-Myers Squibb 2010 includes:

Detailed company profile including:
- Full contact details
- Business developer contact details including name, title, email and telephone (where available)
- Marketed indications
- Pipeline indications
- Partnering interests and indications
- Partnering activity since 2000
- Current partner companies since 2005
Partnering activity since 2005 by:
- Deal type
- Stage of development
- Therapy area
- Numerous charts showing the dealmaking activity of the company since 2005
- The tools to enable effective and efficient preparation for partnering negotiation with the company
- Listing of contract documents between the company and its partners
- The leading M&A and partnering deals by value 2005-2009
- Most active M&A and partnering dealmakers 2005-2009
EXECUTIVE SUMMARY

CHAPTER 1 – INTRODUCTION

CHAPTER 2 – BIGPHARMA – THE TOP 50

CHAPTER 3 – MOST ACTIVE BIGPHARMA DEALMAKERS

3.1 Bigpharma M&A activity
3.2 Bigpharma partnering

CHAPTER 4 – TOP BIGPHARMA DEALS BY VALUE

4.1 Bigpharma M&A
4.2 Bigpharma partnering

CHAPTER 5 – SUBMITTING OPPORTUNITIES TO BIGPHARMA SUCH AS BRISTOL-MYERS SQUIBB

5.1 How to submit an opportunity
5.2 Opportunity submission template
5.3 Sending emails
5.4 Face to face at partnering events
5.5 Online submission forms

CHAPTER 6 – FORTHCOMING BIGPHARMA PARTNERING EVENTS

6.1 Forthcoming events

CHAPTER 7 – BRISTOL-MYERS SQUIBB – THERAPY LOCATOR

7.1 How to use the therapy matrix tables
7.2 Therapeutic area definitions
7.3 Bristol-Myers Squibb – Therapeutic target matrix – marketed and pipeline compounds
7.5 Bristol-Myers Squibb – Therapeutic target matrix – expressed partnering interests
7.6 Bristol-Myers Squibb – Therapeutic target matrix – recent deals – 2005-2009

CHAPTER 8 – BIGPHARMA COMPANY PROFILES – BRISTOL-MYERS SQUIBB

8.1 How to use company profiles
8.2 Field definitions
8.3 Bristol-Myers Squibb company profile
  Company contact details
  Subsidiary companies
  Primary therapy areas
  Business development contacts
  Company description
  Marketed therapeutic indications
  Pipeline (phase I-III) therapeutic indications
  Partnering interests
  Partnering interests - therapeutic indications
  Partnering frequency per annum - 2000-2009
  Current partner companies (2005-2009)
  Recent deals 2005-2009
  By deal type
  By stage of development
  By therapy area
  Contract documents - link direct to each document

FIGURES IN REPORT

Figure 1: Bigpharma – top 50 by pharma sales
Figure 2: Leading Bigpharma M&A companies, 2005-2009
Figure 3: Bigpharma M&A activity – top 50 by pharma sales
Figure 4: Leading Bigpharma partnering companies, 2005-2009
Figure 5: Bigpharma partnering activity – top 50 by pharma sales
Figure 6: Leading M&A deals involving bigpharma by value, 2005-2009
Figure 7: Leading partnering deals by value, 2005-2009
Figure 8: Typical partnering opportunity submission template
Figure 9: Therapeutic area definitions
Figure 10: Therapeutic target matrix – marketed and pipeline compounds
Figure 11: Therapeutic target matrix – expressed partnering interests
Figure 12: Therapeutic target matrix – recent deals 2005-2009
Figure 13: Company profile template and definitions used in report
Figure 14: Bristol-Myers Squibb – Dealmaking frequency 2000-2009
Figure 15: Bristol-Myers Squibb - recent deals (2005-2009) by deal type
Figure 16: Bristol-Myers Squibb - recent deals (2005 – 2009) by stage of development
Figure 17: Bristol-Myers Squibb – recent deals (2005 – 2009) by therapy area
Figure 18: Recent Bristol-Myers Squibb partnering deals (2003-2009) where contract document available
Figure 19: Online partnering resources

Ask Your Question

Partnering Agreements with Bristol-Myers Squibb
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: